GGrantIndex
← Leaderboards

Jonathan H Kaufman

Lipella Pharmaceuticals, Inc.

$8,856,605
Attributed
$8,961,884
Total exposure
11
Grants
11
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.3M · FY200623
$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$8,961,884 · 11

By mechanism

R44$4,599,850 · 4
R42$2,728,394 · 2
SB1$998,466 · 1
R43$410,175 · 3
R41$224,999 · 1

Top collaborators

Others in their field

Top investigators on “Pharmacologic Substance

Research focus

Pharmacologic SubstanceBladderIntravesicalFundingInterstitial CystitisLiposomesSmall Business Innovation Research GrantSafetyRattusPharmaceutical PreparationsUnited States National Institutes Of HealthGrantMarketingMedicalAffectClinical TrialsProgramsSymptomsPre-ClinicalDesignClinical ResearchLifeDrug FormulationsCaring

Grant awards (23)

Phenotyping Interstitial Cystitis/Bladder Pain Syndrome by ICE-MRI Based Bladder Permeability Assay$680,049
R44 · FY2023 · DK · contact PI
Phenotyping Interstitial Cystitis/Bladder Pain Syndrome by ICE-MRI Based Bladder Permeability Assay$673,049
R44 · FY2022 · DK · contact PI
Measuring Bladder Permeability with MRI Using a Novel Contrast Agent Formulation$585,001
R42 · FY2019 · DK · contact PI
Measuring Bladder Permeability with MRI Using a Novel Contrast Agent Formulation$656,417
R42 · FY2018 · DK · contact PI
Clinical Development of Tacrolimus for Hemorrhagic Cystitis$484,221
SB1 · FY2018 · DK · contact PI
Clinical Development of Tacrolimus for Hemorrhagic Cystitis$514,245
SB1 · FY2017 · DK · contact PI
Rapid Point-of-Care Diagnostic Kit for Mosquito Borne Diseases in Urine$210,558
R43 · FY2017 · AI · contact PI
Preclinical Development of Tacrolimus for Radiation Cystitis$629,914
R44 · FY2016 · DK · contact PI
Preclinical Development of Tacrolimus for Radiation Cystitis$648,461
R44 · FY2015 · DK · contact PI
Developing Intravesical Liposomes for Interstitial Cystitis$373,022
R42 · FY2015 · DK · contact PI
Measuring Bladder Permeability with MRI using a Novel Contrast Agent Formulation$224,999
R41 · FY2015 · DK · contact PI
Developing Intravesical Liposomes for Interstitial Cystitis Suppliment request for NIH Exhibiting companies at BIO International$5,000
R42 · FY2015 · DK · contact PI
Developing Intravesical Liposomes for Interstitial Cystitis$368,266
R42 · FY2014 · DK · contact PI
Preclinical Development of Tacrolimus for Radiation Cystitis$222,176
R44 · FY2014 · DK · contact PI
Bladder drug delivery using intravesical liposomes to treat overactive bladder$498,910
R44 · FY2012 · DK · contact PI
Bladder drug delivery using intravesical liposomes to treat overactive bladder$497,291
R44 · FY2011 · DK · contact PI
Developing Intravesical Liposomes for Interstitial Cystitis$239,516
R42 · FY2011 · DK · contact PI
Developing Intravesical Liposomes for Interstitial Cystitis$344,608
R42 · FY2010 · DK · contact PI
Intravesical Liposome Treatment for Interstitial Cystitis$375,000
R44 · FY2009 · DK · contact PI
Developing Intravesical Liposomes for Interstitial Cystitis$156,564
R42 · FY2009 · DK · contact PI
Bladder drug delivery using intravesical liposomes to treat overactive bladder$100,000
R43 · FY2009 · DK · contact PI
Intravesical Liposome Treatment for Interstitial Cystitis$375,000
R44 · FY2008 · DK · contact PI
Intravesical Liposome Treatment for Interstitial Cystitis$99,617
R43 · FY2006 · DK · contact PI